Activity Planner/Director, Moderator:

Ilana Schlam, MD, MPH 
Clinician, Dana Farber Cancer Institute, Harvard Medical School

Dr. Schlam received her medical degree from Anahuac University in Mexico City in 2014. She subsequently completed her Internal Medicine residency at The Jewish Hospital of Cincinnati and then her Hematology and Medical Oncology fellowship at the MedStar Georgetown Washington Hospital Center in Washington, DC. She obtained her Master of Public Health degree from the Harvard School of Public Health in 2024. She was faculty at Tufts Medical Center from 2021 to 2024. In 2024, she joined the staff of the Dana-Farber Cancer Institute as a breast medical oncologist and clinical researcher. Her research focuses on drug development and identifying markers of response to novel therapies. 

Speakers:

Claudine Isaacs, MD, FRCPC, FASCO 
Professor of Medicine and Oncology
Associate Director, Clinical Research
Lombardi Comprehensive Cancer Center
Georgetown University

Dr. Isaacs is Professor of Medicine and Oncology, Associate Director for Clinical Research, and Leader of the Clinical Breast Cancer Program at the Lombardi Comprehensive Cancer Center (LCCC) at Georgetown University.  She has extensive experience in the conduct of clinical trials focusing on early-stage and metastatic breast cancer and currently serves as Co-Chair of the Endocrine Resistance Working Group of the Translational Breast Cancer Research Consortium (TBCRC) and as Chair of the Clinical Trials Operations Working Group for the I-SPY 2 Trial. She has authored more than 300 peer-reviewed publications and has served on a number of national committees.

Sarah Sammons, MD
Associate Director, Metastatic Breast Cancer Program
Susan F. Smith Center for Women’s Cancers
Dana-Farber Cancer Institute 
Assistant Professor of Medicine, Harvard Medical School

Dr. Sammons is an Associate Clinician at Dana-Farber Cancer Institute in Boston, MA, and faculty member of Harvard Medical School. Her clinical focus is on the treatment of all stages of breast cancer. She completed her fellowship in medical oncology and hematology at Duke University Hospital. In 2018, she joined the staff of Duke Cancer Institute and served as Associate Director of Breast Cancer Research. She joined Brigham and Women's Hospital and Dana-Farber Cancer Institute in 2022, where she serves as Associate Director of the Metastatic Breast Cancer Program. She is interested in developing novel systemic therapies to improve outcomes for patients facing breast cancer. 

Komal Jhaveri, MD, FACP
Associate Attending, Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Patricia and James Cayne Chair for Junior Faculty
Department of Medicine, Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine, Weill Cornell Medical College, New York, NY

Dr. Jhaveri is an Associate Attending Physician at Memorial Sloan Kettering Cancer Center (MSKCC), where she also serves as Section Head for the Endocrine Therapy Research Program within the Breast Medicine Service and as the Clinical Director for the Early Drug Development Service. She is an Associate Professor in the Department of Medicine (DOM) at Weill Cornell Medicine in New York. She earned her medical degree from the University of Mumbai, where she then completed training in nuclear medicine. She later completed her Internal Medicine residency from Icahn School of Medicine at Mount Sinai (Morningside/West) Program in New York and her Medical Oncology/ Hematology fellowship at MSKCC. From July 2012 to May 2015, she served as an Assistant Professor in the DOM at New York University and as an Attending Physician at the Langone Medical Center and at Bellevue Hospital.

Dr. Jhaveri’s research interests focus on the development of improved therapies for patients with breast cancer, by conducting novel clinical trials integrated with translational biomarker work through acquired biospecimen (cfDNA and tumor) or imaging analyses. She has led the development of PI3K/Akt inhibitors, FGFR inhibitors, ERBB2 inhibitors, oral SERDs, and antibody-drug conjugates, amongst others. 

Planners/Reviewers:

Ole-Petter R. Hamnvik, MB BCh BAO, MMSc, MRCPI 
Program Director, Endocrinology Fellowship, Brigham and Women’s Hospital  
Associate Professor of Medicine, Harvard Medical School  
Education Editor, NEJM Group

Christine H. Bruce, DMSc, MHSA, PA-C 
Associate Professor and Program Director, Penn State University Physician Assistant Program 

Kristin Wason, MSN, AGPCNP, CARN 
Addiction Clinical Educator: Office Based Addiction Treatment, Boston Medical Center 
Nurse Practitioner, Assistant Professor: Boston University School of Medicine 
Education Lead: Grayken Addiction Nurse Fellowship